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Abstract
Pulmonary vascular arterial remodeling is an integral and well-understood component of pulmonary hypertension (PH). In
contrast, morphological alterations of pulmonary veins in PH are scarcely described. Explanted lungs (n¼ 101) from transplant
recipients with advanced chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary arterial hypertension
(IPAH) were analyzed for venous vascular involvement according to a pre-specified, semi-quantitative grading scheme,
which categorizes the intensity of venous remodeling in three groups of incremental severity: venous hypertensive (VH)
grade 0¼ characterized by an absence of venous vascular remodeling; VH grade 1¼ defined by a dominance of either
arterialization or intimal fibrosis; and VH grade 2¼ a substantial composite of arterialization and intimal fibrosis. Patients
were grouped according to clinical and hemodynamic characteristics in three groups: COPD non-PH, COPD-PH, and IPAH,
respectively. Histological specimens were examined by a cardiovascular pathologist blinded to clinical and hemodynamic data.
Pathological alterations of pulmonary veins were present in all hemodynamic groups, with the following incidences of VH
grade 0/1/2: 34/66/0% in COPD non-PH; 19/71/10% in COPD-PH; and 11/61/28% in IPAH. In COPD, explorative correlation
analysis of venous remodeling suggested a modest positive correlation with systolic and mean pulmonary artery pressure
(P¼ 0.032, respectively) and an inverse modest correlation with diffusion capacity for carbon monoxide (P¼ 0.027). In add-
ition, venous remodeling correlated positively with the degree of arterial remodeling (P¼ 0.014). In COPD-PH and IPAH,
advanced forms of pulmonary venous remodeling are present, emphasizing that the disease is not exclusively restricted to
arterial lesions. In addition, venous remodeling may be related to the hemodynamic severity, but more rigorous analysis is
required to clearly define potential relationships.
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Pulmonary hypertension (PH) is a hemodynamic patho-
physiological disorder involving the pulmonary circulation
and the right ventricle. The pathogenesis of PH includes
pulmonary arterial vascular remodeling, which is an integral
and well described component caused by several complex
cellular and molecular mechanisms.1 Arterial remodeling
aﬀects all three layers of the arterial vasculature, thereby
narrowing or obstructing the lumen and disrupting vascular
compliance and distensability.2 By contrast, limited infor-
mation regarding the involvement of pulmonary veins
exists. It is increasingly believed that venous abnormalities
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may be relevant in many clinical PH phenotypes besides
pulmonary veno-occlusive disease (PVOD).3
This retrospective study examined explanted lungs from
transplant recipients with an emphasis on pulmonary
venous vascular remodeling in PH secondary to chronic
obstructive pulmonary disease (COPD-PH) and idiopathic
pulmonary arterial hypertension (IPAH). Speciﬁcally, the
study objectives were to identify, examine, and classify pul-
monary venous lesions. Next, to relate venous vascular
remodeling in advanced COPD to hemodynamic and pul-
monary function variables in advanced COPD. Lastly, to
describe a potential correlation between the severity of arter-
ial and venous remodeling in advanced COPD.
Methods
This was a retrospective investigation of explanted lungs
from transplant recipients diagnosed with advanced
COPD and IPAH at Copenhagen University Hospital,
Rigshospitalet, Denmark during 1991–2015. During this
period, 361 advanced COPD patients underwent lung trans-
plantation and parallel hemodynamic assessment by right-
heart catheterization (RHC) as part of the transplantation
work-up program. The analysis of explanted lungs in COPD
was focused on hemodynamic distinction based on the pres-
ence or absence of PH designated by the mean pulmonary
artery pressure (mPAP), as follows: (1) COPD non-PH,
deﬁned by mPAP< 25mmHg; and (2) COPD-PH, deﬁned
by mPAP 25mmHg and pulmonary artery wedge pressure
(PAWP) 15mmHg. These groups were compared to
patients with IPAH. Patients with COPD-PH and
PAWP> 15mmHg were excluded from analysis due to a
possible post-capillary contribution. We randomly selected
35 of 196 COPD non-PH patients for inclusion. The COPD-
PH group comprised 35 of 119 patients with mild–moderate
COPD-PH (mPAP 25–34mmHg) who were randomly
selected, as well as 13 of 15 patients with severe COPD-
PH (mPAP 35mmHg; unavailable histological material
in the remaining two patients) (Fig. 1). COPD patients
were compared to 18 patients with IPAH. Clinical charac-
teristics and description of pulmonary arterial remodeling
related to the PH component in the advanced COPD
cohort has previously been thoroughly described.4,5
Transplant recipients met the criteria for lung transplant-
ation in accordance with International Society for Heart
and Lung Transplantation guidelines at the time of listing.6
Histological analysis of pulmonary veins
Explanted lungs were formalin-inFated overnight after the
transplantation procedure before being extensively sampled
and embedded in parafEn. Sections (two to three from each
lobe) were stained with hematoxylin and eosin (H&E). In
addition, some sections were stained with Masson’s tri-
chrome, Verhoeﬀ or with combined Alcian, Orcein and
Van Gieson stains for elastin. Sections were assessed by
the same experienced pulmonary cardiovascular patholo-
gist, who was blinded to clinical and hemodynamic data.5
Pulmonary veins were identiﬁed by their anatomical
localization to distinguish them from pre-capillary vessels.
Accordingly, veins were identiﬁed in the periphery of lung
lobules in the interlobular septae and trabeculae, whereas
smaller pulmonary venous branches were recognized by
their position adjacent to, but not appositional to, bronch-
ovascular bundles. Serial sections were used to track and
conﬁrm connection to the larger veins localized in the tra-
beculae. The study focused solely on the vascular changes
observed in inter- and intra-lobular pulmonary veins.
A semi-quantitative grading scheme, which was pre-spe-
ciﬁed before analysis, was used to determine pulmonary
venous hypertensive (VH) remodeling of increasing com-
plexity (Table 1). The distinct groups are broadly character-
ized by: VH grade 0¼ non-remodeled veins; VH grade
1¼predominance of either intimal ﬁbrosis or
Advanced COPD LTx recipients 
with RHC data 
n = 361 
COPD-PH 
(mPAP ≥ 25 mmHg, PAWP ≤ 15 mmHg) 
n = 125 
COPD non-PH 
(mPAP < 25 mmHg) 
n = 196 
Study populaon 
COPD-PH 
n = 48 
COPD non-PH 
n = 35 
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n = 18 
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Figure 1. Study population. A total of 101 explanted lungs from transplant recipients with RHC data from pre-transplant hemodynamic
evaluation. A random selection of 35/196 COPD non-PH patients were included in the analysis. Forty-eight patients with pre-capillary COPD
were included, comprising a random selection of 35/110 patients with mild–moderate pre-capillary PH (mPAP 25–34mmHg) and 13/15 with
severe pre-capillary COPD-PH (unavailable histological material in two patients). Explanted lungs from 18 patients with IPAH were used as
reference.
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arterialization; VH grade 2¼ substantial intimal ﬁbrosis and
arterialization in conjunction. Pulmonary vascular venous
changes were assessed overall and the most severe and wide-
spread vascular lesion determined the overall degree of
venous remodeling as reﬂected by the VH grade.
Statistical analysis
Continuous data are expressed as median (interquartile
range [IQR]). Explorative correlation analysis between ordi-
nal variables and continuous variables was investigated
using Spearman’s rank-order correlation test. Two-tailed
asymptotic signiﬁcance levels are displayed. Correlation
between ordinal variables with expected monotonous rela-
tionship was analyzed using Goodman and Kruskal’s
Gamma (IBM SPSS/PAWP Statistics 22, Armonk, NY,
USA). A signiﬁcance level of a¼ 0.05 was applied.
Results
Venous remodeling was explored in COPD non-PH
(n¼ 35), pre-capillary COPD-PH (n¼ 48), and IPAH
(n¼ 18) patients. Consequently, explanted lungs from 101
transplant recipients with increasing hemodynamic severity
were analyzed (Fig. 1). Baseline characteristics are summar-
ized in Table 2. The median time from evaluation to trans-
plantation was 372 (IQR¼ 194–777) days.
Pathological alterations of veins were present in all
groups, with the following incidences of VH grade 0/1/2:
34/66/0% in COPD non-PH; 19/71/10% in COPD-PH;
and 11/61/28% in IPAH (Fig. 2). Fig. 3 illustrates the spec-
trum of pulmonary venous remodeling according to the
introduced grading scheme, with elastin stains particularly
related to remodeled veins.
Accordingly, the highest incidence of severe venous
remodeling, corresponding to VH grade 2, was observed
in IPAH, with a lower incidence in the COPD-PH group,
but was not detected in COPD non-PH. Similarly, the
lowest proportion of non-remodeled veins (VH grade 0)
was observed in IPAH, while most frequently observed in
COPD non-PH. Intimal ﬁbrosis, usually without elaborate
arterialization (VH grade 1), was quite evenly distributed
among the groups.
Venous remodeling in COPD
Analysis of COPD patients showed that the extent of venous
remodeling, assessed by VH grade scores, was statistically
signiﬁcantly higher in COPD-PH than in COPD non-PH
(median rank 45.92 versus 36.63, Mann–Whitney U-test
P¼ 0.033).
Explorative correlation analyses were conducted to assess
the relationship between venous remodeling and hemo-
dynamic indices in advanced COPD. We observed a
modest positive correlation between the degree of venous
remodeling, assessed by VH grade scores, and the systolic
PAP (rs¼ 0.239, P¼ 0.032) as well as the mPAP
(rs¼ 0.235, P¼ 0.032), whereas remaining hemodynamic
indices did not correlate to the degree of venous remodeling
(Table 3, Fig. 4).
Diﬀusion capacity for carbon monoxide (DLCO) corre-
lated modestly and inversely to the degree of venous
remodeling (rs¼0.285, P¼ 0.027; DLCO % of predicted
rs¼0.246, P¼ 0.056), while no other pulmonary function
variable correlated signiﬁcantly (Table 3). Moreover, the
analysis did not demonstrate a correlation between the
extent of venous remodeling and PaO2 (rs¼0.018,
P¼ 0.883) or PaCO2 (rs¼ 0.202, P¼ 0.086) (Table 3, Fig. 4).
Arterio-venous remodeling relationship in COPD
Progressive arterial lesions previously described in explanted
lungs of advanced COPD patients, assessed by a modiﬁed
Heath–Edwards (HE) six-grade classiﬁcation scheme,5,7
were included in a correlation analysis. Of 84 COPD
patients included in this study, six (7%) showed no struc-
tural alterations, 24 (29%) presented with medial thickening
of muscular arteries, 25 (30%) displayed further cellular
intimal proliferation, and 26 (31%) had additional concen-
tric intimal ﬁbrosis, corresponding modiﬁed HE grades 0–3.
Table 1. Semi-quantitative grading scheme describing pulmonary venous hypertensive (VH) lesions of increasing complexity.
0 No discernible pulmonary venous remodeling
- Thin-walled vessel
- Narrow fibrous intima and discrete muscle layer
- Single elastic lamina
1 Arterialization or intimal fibrosis
- Intimal fibroelastic thickening and increased cellularity (myofibroblastic)
- Mild elastic lamina duplication/splitting tendency
- Mild combinations of arterialization (smooth muscle cell hypertrophy) and intimal fibrosis can occur
2 Arterialization and intimal fibrosis
- Intimal fibrotic thickening and increased cellularity due to myofibroblast proliferation and deposition of collagen and elastin
- Severe elastic lamina duplication/splitting and multi layering (often fully concentric)
- Generally more severe arterialization and intimal fibrosis
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Table 2. Clinical baseline characteristics.
COPD
Non-PH COPD-PH IPAH
(n¼ 35) (n¼ 48) (n¼ 18)
Age (years) 52.9 (48.7–58.8) 54.8 (50.6–58.4) 31.3 (20.6–47.8)
BMI (kg/m2) 20.1 (18.5–24.6) 21.8 (18.8–24.1) 23.2 (20.5–25.7)
Gender (No. female [%]) 23 (66) 21 (44) 12 (67)
Arterial blood gas values (mmHg)
PaO2 66.3 (60.7–72.3) 63.4 (55.7–71.7) 68.2 (56.6–74.8)
PaCO2 42.0 (38.3–47.3) 46.2 (42.7–57.4) 29.6 (26.4–33.0)
Pulmonary function tests
FEV1 (L) 0.7 (0.6–0.8) 0.6 (0.5–0.7) 2.4 (1.7–3.4)
FEV1 (% predicted) 23.6 (20.8–30.4) 18.6 (15.0–22.7) 84.7 (71.5–87.0)
FVC (L/s) 1.9 (1.5–2.2) 1.7 (1.3–2.1) 3.1 (2.6–4.3)
FVC (% predicted) 57.5 (48.3–66.1) 42.0 (33.3–57.0) 88.0 (81.3–95.5)
FEV1/FVC (s
–1) 0.4 (0.3–0.4) 0.4 (0.3–0.4) 0.8 (0.7–0.8)
TLC (L) 7.6 (6.2–8.6) 8.1 (6.8–9.3) 4.8 (4.4–6.3)
TLC (% predicted) 128 (113–146) 129 (117–143) 98 (91–103)
RV (L) 5.2 (3.9–5.9) 6.2 (4.7–7.1) 1.7 (1.4–2.4)
RV (% predicted) 259 (226–304) 295 (242–330) 116 (93–126)
DLCO (mmol/min/kPa) 2.4 (1.8–3.7) 1.9 (1.4–2.6) 5.4 (4.5–5.6)
DLCO (% predicted) 30.4 (20.5–41.1) 22.5 (15.2–25.7) 56.0 (45.5–72.2)
KCO (mmol/min/kPa/L) 0.6 (0.4–0.8) 0.5 (0.4–0.7) 1.2 (1.0–1.4)
KCO (% predicted) 41.0 (26.3–51.0) 32.2 (23.0–43.1) 61.2 (31.6–68.7)
Hemodynamics
PAP (mmHg)
Systolic 28 (25–31) 43 (37–48) 83 (74–103)
Diastolic 14 (8–17) 22 (19–26) 39 (30–45)
Mean 18 (14–22) 30 (27–36) 53 (48–70)
mRAP (mmHg) 5 (4–6) 9 (7–10) 8 (6–16)
PAWP (mmHg) 9 (8–11) 12 (10–14) 16 (10–21)
CO (L/min) 5.0 (4.2–5.8) 5.5 (4.6–6.8) 3.5 (3.0–4.4)
CI (L/min/m2) 2.9 (2.6–3.4) 3.0 (2.7–3.6) 2.0 (1.6–2.6)
PVR (WU) 1.8 (1.0–2.6) 3.5 (2.7–4.3) 11.7 (8.4–17.6)
BMI, body mass index; CI, cardiac index; CO, cardiac output; COPD, chronic obstructive pulmonary disease; DLCO, diffusion capacity for carbon monoxide; FEV1,
forced expiratory volume in 1 s; FVC, forced vital capacity; IPAH, idiopathic pulmonary arterial hypertension; KCO; carbon monoxide transfer coefficient; mRAP,
mean right atrial pressure; PaCO2, partial pressure of arterial carbon dioxide; PaO2, partial pressure of arterial oxygen; PAP, pulmonary artery pressure; PAWP,
pulmonary artery wedge pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RV, residual volume; TLC, total lung capacity.
Figure 2. Incidences of venous remodeling in pre-specified groups according to the severity of venous remodeling assessed by VH-classification.
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Two (2%) had additional complex structural lesions com-
prising plexiform lesions with or without angiomatoid
lesions, corresponding to modiﬁed HE grades 4–5, while
no COPD patient presented with necrotizing arteritis (mod-
iﬁed HE grade 6). The degree of venous remodeling in
COPD, as denoted by VH classiﬁcation, correlated posi-
tively and moderately to the severity of arterial remodeling
(G¼ 0.408, P¼ 0.014).
Discussion
This study describes the frequency and severity of venous
structural lesions in IPAH as well as advanced COPD with
and without accompanying PH. While arterial remodeling is
well-documented, venous remodeling is increasingly attract-
ing attention in diﬀerent forms of PH. However, pulmonary
veins remain diﬃcult to study. Lung venous endothelium
and smooth muscle cells lack unique molecular markers to
aid identiﬁcation and distinction from pre-capillary vessels
in humans.8 In this study, the anatomical localization was
used to isolate veins, which provides a histological distin-
guishing feature of the present.
Severe venous remodeling, a composite of substantial
arterialization and intimal ﬁbrosis (VH grade 2), was exclu-
sively observed in patients with PH, and most frequently in
IPAH. Moreover, the majority of IPAH patients predomin-
antly displayed intimal ﬁbrosis with subtle features of arteri-
alization in veins (VH grade 1). Thus, structural alterations
of the venous vasculature seem apparent in IPAH,
suggesting that the disease is not exclusively restricted to
the arterial vasculature, thereby challenging the traditional
dogma. This ﬁnding is in agreement with observed increases
in intimal and adventitial thickness of pulmonary venous
walls in primary PH9 and recently described pronounced
muscular remodeling of septal veins in PAH lungs carrying
BMPR2 mutation.10 It is noteworthy that the observed
intensity of venous intimal ﬁbrosis, irrespective of assigned
grade, was not as severe as is typically characteristic for the
extensive and diﬀuse ﬁbrous occlusion of veins in PVOD11,12
(Fig. 5). Furthermore, plexiform lesions (focal obliterative
lesions of endothelial cell channels lined by smooth muscle
cells, myoﬁbroblasts and connective tissue matrix, typically
considered a hallmark of PAH13) were present in 17 of 18
IPAH patients, which are not routinely observed in
PVOD.14
The pathogenic pathways and possible genetic mediators
accountable for pulmonary venous remodeling remain
unknown, although mutations in EIF2AK4 have been
linked PVOD.15 Nonetheless, venous remodeling may be
more common in diﬀerent clinical forms of PH than antici-
pated. Venous ﬁbrotic lesions have been identiﬁed in chronic
thromboembolic PH16 while both arterialization as well as
increased media, intima, and adventitial thickness of pul-
monary veins in PH secondary to left heart disease have
been described.17–19 Here, we extensively describe venous
remodeling in COPD. Histological analysis showed that
intimal ﬁbrosis with subtle arterialization (VH grade 1)
was frequent in COPD-PH. It was also apparent in the
Figure 3. Histological examples of venous vascular remodeling. (a, b) VH grade 0¼ vein without remodeling. Thin-walled vessel with discrete
intima, delicate single-layered elastic lamina and discernable smooth muscle cells (H&E staining). (c, d) VH grade 1¼ veins with increased vessel
wall thickness, mainly due to fibroelastic deposition in the intima and a slight degree of myofibroblast proliferation. Prominent splitting/duplication
of the elastic lamina. ((c) H&E staining; (d) Alcian/van Gieson/elastin staining). (e, f) VH grade 2¼ increased vessel wall thickness, with more
pronounced collagen and elastin deposition including myofibroblast proliferation in the intima and media. Multilayering of a split/duplicated elastic
lamina in a concentric pattern combined with smooth muscle cell hypertrophy. ((e) Alcian/van Gieson/elastin staining; (f) Verhoeff staining).
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COPD non-PH group, which may be expected given the fact
that even arterial remodeling is evident in smokers and in
COPD without PH.5,20 Furthermore, the COPD non-PH
group surely included patients with ‘‘borderline-PH’’ hemo-
dynamic characteristics, in whom a vascular component and
future manifest PH is likely as a consequence of hemo-
dynamic progression.21,22 However, the composite of
marked arterialization and intimal ﬁbrosis (VH grade 2)
was only identiﬁed in COPD, when PH was present.
Accordingly, advanced venous lesions similar to those
observed in IPAH can be observed in COPD when PH is
present. Interestingly, explorative correlation analysis sug-
gested a positive relationship between the degree of venous
remodeling and hemodynamic severity in COPD. More spe-
ciﬁcally, correlation to systolic and mPAP was observed.
The relationship was modest and should be interpreted
with respect to the variability and study design.
Nevertheless, the association seems physiologically congru-
ent and in accordance with the previously described
(stronger) association between arterial structural lesions
and hemodynamic severity in advanced COPD.5 Whether
venous remodeling, in this context, represents a cause or
Table 3. Correlation between venous remodeling and clinical vari-
ables in COPD.
Venous remodeling
Correlation coefficient P value
Age (years) 0.162 0.148
BMI (kg/m2) 0.060 0.597
Arterial blood gas values
PaO2 (mmHg) 0.018 0.883
PaCO2 (mmHg) 0.202 0.086
Pulmonary function tests
FEV1 (L) 0.153 0.173
FEV1 (% predicted) 0.148 0.191
FVC (L/s) 0.151 0.178
FVC (% predicted) 0.173 0.128
FEV1/FVC (s
1) 0.005 0.961
TLC (L) 0.017 0.633
TLC (% predicted) 0.056 0.633
RV (L) 0.039 0.749
RV (% predicted) 0.034 0.778
DLCO (mmol/min/kPa) 0.285 0.027
DLCO (% predicted) 0.246 0.056
KCO (mmol/min/kPa/L) 0.185 0.149






mRAP (mmHg) 0.023 0.869
PAWP (mmHg) 0.198 0.080
CO (L/min) 0.014 0.910
CI (L/min/m2) 0.128 0.331
PVR (WU) 0.133 0.261
BMI, body mass index; CI, cardiac index; CO, cardiac output; COPD, chronic
obstructive pulmonary disease; DLCO, diffusion capacity for carbon monoxide;
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; KCO; carbon
monoxide transfer coefficient; mRAP, mean right atrial pressure; PaCO2, partial
pressure of arterial carbon dioxide; PaO2, partial pressure of arterial oxygen;
PAP, pulmonary artery pressure; PAWP, pulmonary artery wedge pressure;
PVR, pulmonary vascular resistance; RV, residual volume; TLC, total lung
capacity.
Figure 4. Plots of selected correlations according to VH-grade
allocation.
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consequence of hemodynamic worsening remains to be clar-
iﬁed. Notably, the degree of arterial and venous remodeling
in COPD correlated positively suggesting that both pre-
capillary and post-capillary vessels in COPD react to stimuli
which promote vascular remodeling. Chronic exposure to
hypoxia plays a pivotal role in the development of arterial
remodeling.23 Pulmonary veins, similar to pulmonary
arteries, exhibit high sensitivity to hypoxia24 and chronic
exposure can perpetuate venous arterialization,25 which is
in keeping with the overall observations of venous remodel-
ing in advanced COPD. It should be mentioned that simul-
taneous presence of both noteworthy arterial and venous
lesions not necessarily implied severe COPD-PH. This
could suggest that ‘‘vascular phenotypes’’ in COPD-PH
may also be evident in the mild–moderate COPD-PH spec-
trum. Interestingly, venous remodeling correlated negatively
to DLCO in the explorative correlation analysis.
Consequently, DLCO may potentially aid identiﬁcation of
COPD patients with noteworthy venous remodeling alike
its supportive role in detection of PVOD in presumed
PAH.26 In this context, it is noteworthy that DLCO has
been identiﬁed as an independent predictor of mortality in
COPD-PH.27
Various PH phenotypes, including COPD-PH and IPAH
as shown, seem to include structural alterations of
veins,16–19 whereas PVOD ultimately represents a rare mani-
festation of PH with excessive venous structural changes.28
The consequences of venous remodeling in non-PVOD PH
are unknown. In particular, the speciﬁc inﬂuence of venous
remodeling on the eﬃcacy of pharmacological PAH treat-
ment requires clariﬁcation. At present, it is challenging to
relate vascular remodeling to responsiveness of pharmaco-
logical therapies or outcome, since sequential routine or
even experimental biopsies are avoided due to the risk of
severe complications in PH. Nonetheless, elaborate
remodeling of post-capillary vessels in PH may aggravate
the clinical course and alter the response to speciﬁc PAH
therapy, similar to its role in PVOD.12 Surely, the identiﬁ-
cation of pathogenic pathways, genetic mediators, and novel
methods to identify patient phenotypes with venous
remodeling is necessary to allow for a better understanding
of the clinical implications of venous involvement in PH and
may provide a basis for treatment diﬀerentiation.
Certain limitations of the study should be borne in mind.
First, pulmonary veins are histologically diﬃcult to distin-
guish from arteries. Given the current lack of unique pul-
monary venous molecular markers, the anatomical
localization is a reasonable distinctive feature although aber-
rations may occur in disease states. The analysis concerned a
uniﬁed assessment of both inter- and intralobular veins (i.e.
septal and non-septal veins) without uniform random sam-
pling. Accordingly, the study does not allow for deﬁnite con-
clusion regarding the hetero- or homogeneity of remodeling
in septal versus non-septal veins or the dissemination of
venous remodeling related to particular lung segments.
Subjectively, both septal and non-septal veins in a particular
specimen presented with similar degrees of remodeling,
which furthermore seemed to be equally distributed through-
out the respective lung segments. Second, semi-quantitative
analysis relies on subtle diﬀerences and could be subject to
interpretation bias despite our eﬀorts to avoid bias by blind-
ing the observer to clinical and hemodynamic characteristics.
Accordingly, the study design and methodology should be
considered in the interpretation of the results. Nonetheless, a
planimetric description is a relevant and a natural ﬁrst step
before more extensive and rigorous analysis with prospective
computerized morphometric analysis of perfusion-ﬁxated
and dye-injected venous vessels, which can provide add-
itional detailed insights of the venous structure, despite
inherent diﬃculties of vessel calibration due to post-
mortem vessel contraction.29 Third, histological samples
from explanted lungs may not be representative of the
pathoanatomy during evaluation for transplantation. As
the evolution of the vascular remodeling component over
time is incompletely understood, pulmonary vascular alter-
ations may have occurred after index RHC.
In conclusion, venous remodeling comprising intimal
ﬁbrosis and features of arterialization to a variable extent,
is frequently encountered in advanced COPD and IPAH.
Occasionally, venous remodeling in COPD reaches the
Figure 5. Venous vascular remodeling in a patient who underwent lung transplantation due to pulmonary veno-occlusive disease at our
institution. (a) Partial and total occlusion of pre-septal veins with loose, cushion-like intimal fibrosis in addition to a slight capillary hemangio-
matosis and numerous siderophages in the alveolar lumina. (H&E staining). (b) Totally obstructed pre-septal vein with occlusive fibroelastosis and
duplication of external elastic lamina (Orcein staining). (c) Sub-totally and severely occluded pre-septal vein with cushion-like loose collagenous
intimal fibrosis (H&E staining).
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same advanced degree as in IPAH, when PH is present. In
exploratory correlation analysis, venous remodeling in
COPD correlated with the hemodynamic severity, diﬀusion
capacity for monoxide, and the extent of arterial remodel-
ing. This ﬁnding needs further clariﬁcation by use of state-
of-the-art morphometric analysis suitable for PH. The
clinical importance of venous remodeling in PH and the
implications for PAH speciﬁc treatment require further
investigation.
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